Chugai Pharmaceutical Co., Ltd. (CHGCY) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Drug Manufacturers - General Branche. Der Hauptsitz des Unternehmens ist in Tokyo, Japan. Der aktuelle CEO ist Osamu Okuda.
CHGCY hat IPO-Datum 2012-08-03, 5,026 Vollzeitbeschäftigte, gelistet an der Other OTC, eine Marktkapitalisierung von $88.77B.
Chugai Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing, and global distribution of innovative medicines. The company maintains a diversified portfolio spanning oncology, osteoporosis, renal diseases, and neurology, with key marketed products including Avastin, Tecentriq, Herceptin, Actemra, and Hemlibra, alongside a robust pipeline of development candidates across multiple therapeutic areas. As a subsidiary of Roche Holding Ltd., Chugai leverages strategic alliances and collaborative research partnerships to advance its drug development initiatives. Founded in 1925 and headquartered in Tokyo, the company combines decades of pharmaceutical expertise with Roche's global resources and capabilities.
